2023 updates in metastatic colorectal cancer genomic biomarkers

Huge advancements in personalized medicine and the availability of genetic testing have led us to consider the use of genomic alterations as biomarkers in cancer treatment. In this podcast, we will revisit the most recent developments in the efficacy and clinical application of genomic biomarkers in metastatic colorectal cancer (mCRC) presented during 2023. We will hear from Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, regarding the CodeBreak 300 trial (NCT05198934); John H. Strickler, MD, Duke Cancer Institute, Durham, NC, on MOUNTAINEER (NCT03043313); Ardaman Shergill, MD University of Chicago, Chicago, IL, on PARADIGM (NCT02394795), STRATEGIC-1 (NCT01910610) and CAIRO5 (NCT02162563) and Benny Johnson, DO, The University of Texas MD Anderson Cancer Center, Houston, TX, who rounds off the discussion by considering the use of circulating tumor DNA (ctDNA) to assess minimal residual disease (MRD) status. Be sure to visit our dedicated page on genomic biomarkers in metastatic colorectal cancer here to learn more about current and future biomarker testing standards, as well as potential treatment directions in the future.